Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination

Journal of Immunological Methods

Volumn 352, Issue 1-2, 2010, Pages 169-173

  Ardon, H ^a   Verbinnen, B ^a   Maes, W ^a   Beez, T ^a,b   Van Gool, S ^a   De Vleeschouwer, S ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b University Heinrich Heine   (Germany)

Author keywords

CD127; DC vaccination; Foxp3; Glioma; Monitoring; Treg

Indexed keywords

DENDRITIC CELL VACCINE; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL ISOLATION; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REPRODUCIBILITY;

ANTIGENS, CD4; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CANCER VACCINES; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM NEOPLASMS; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE CULTURE TEST, MIXED; MONITORING, PHYSIOLOGIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, AUTOLOGOUS;

EID: 71749115790     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.10.007     Document Type: Article

References (13)

1. De Vleeschouwer S., Fieuws S., Rutkowski S., Van Calenbergh F., Van Loon J., Goffin J., Sciot R., Wilms G., Demaerel P., Warmuth-Metz M., Soerensen N., Wolff J.E., Wagner S., Kaempgen E., and Van Gool S.W. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin. Cancer Res. 14 10 (2008) 3098-3104
2. Dunn G.P., Dunn I.F., and Curry W.T. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 7 (2007) 12
3. Fecci P.E., Mitchell D.A., Whitesides J.F., Xie W., Friedman A.H., Archer G.E., Herndon J.E., Bigner D.D., Dranoff G., and Sampson J.H. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66 6 (2006) 3294-3302
4. Gomez G.G., and Kruse C.A. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther. Mol. Biol. 10 a (2006) 133-146
5. Grauer O.M., Nierkens S., Bennink E., Toonen L.W., Boon L., Wesseling P., Sutmuller R.P., and Adema G.J. CD4 + FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer 121 (2007) 95-105
6. Grauer O.M., Sutmuller R.P., van Maren W., Jacobs J.F., Bennink E., Toonen L.W., Nierkens S., and Adema G.J. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int. J. Cancer 122 (2008) 1794-1802
7. Heimberger A.B., Abou-Ghazal M., Reina-Ortiz C., Yang D.S., Sun W., Qiao W., Hiraoka N., and Fuller G.N. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin. Cancer Res. 14 16 (2008) 5166-5172
8. Jacobs J.F., Idema A.J., Bol K.F., Nierkens S., Grauer O.M., Wesseling P., Grotenhuis J.A., Hoogerbrugge P.M., de Vries I.J., and Adema G.J. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology 11 4 (2008) 394-402
9. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St. Groth B., Clayberger C., Soper D.M., Ziegler S.F., and Bluestone J.A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells 60. J. Exp. Med. 203 7 (2006) 1701-1711
10. Maes W., Rosas G.G., Verbinnen B., Boon L., De Vleeschouwer S., Ceuppens J.L., and Van Gool S.W. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro-Oncology 11 5 (2009) 529-542
11. Rutkowski S., De Vleeschouwer S., Kaempgen E., Wolff J.E.A., Kuhl J., Demaerel P., Warmuth-Metz M., Flamen P., Van Calenbergh F., Plets C., Sorensen N., Opitz A., and Van Gool S.W. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br. J. Cancer 91 (2004) 1656-1662
12. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoom M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E.A., and Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Eng. J. Med. 352 (2005) 987-996
13. Ziegler S.F. FOXP3: of mice and men. Annu. Rev. Immunol. 24 (2006) 209-226